CN1257070A - Process for extracting purified isoliensinine and liensinine from plumula nelumbinis - Google Patents
Process for extracting purified isoliensinine and liensinine from plumula nelumbinis Download PDFInfo
- Publication number
- CN1257070A CN1257070A CN 98121706 CN98121706A CN1257070A CN 1257070 A CN1257070 A CN 1257070A CN 98121706 CN98121706 CN 98121706 CN 98121706 A CN98121706 A CN 98121706A CN 1257070 A CN1257070 A CN 1257070A
- Authority
- CN
- China
- Prior art keywords
- liensinine
- isoliensinine
- water
- crystallization
- plumula nelumbinis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The preparation method for extracting and purifying isoliensinine and liensinine includes the following steps: firstly, using methyl alcohol extraction method to extract water insoluble total alkali with methyl liensinine, isoliensinine and liensinine as main alkali, then separating out strong phenolic total alkali containing isoliensinine and liensinine from water insoluble total alkali, and then using crystallizing process to separate strong phenolic total alkali to obtain the invented isoliensinine and liensinine. As compared with existent technology, the said invention possesses the advantages of low cost, high yield, excellent quality, its content is greater than 90% and suitable for industrial production.
Description
The present invention relates to medical preparation method's, particularly plant amedica extracting and purifying method.
China's cardiovascular and cerebrovascular diseases incidence and mortality ratio occupy first of each disease, are ascendant trend year by year, and the mortality ratio of hypertension palsy, irregular pulse, myocardial infarction, heart failure is high especially.Conventional Chinese medicine Plumula Nelumbinis " clearing away the heart-fire, controlling nocturnal emission with astringent drugs blood ", the essential substance that wherein has cardiac vascular activity be Isoliensinine (Isoliensinine), [Wang Jialing etc. Chinese Pharmaceutical Journal 1992; 27 (6): 359], liensinine (Liensinine) [Chen Weizhou etc. Acta Pharmaceutica Sinica 1962; 9 (5): 277-279] [Xiong Yili, Wang Jialing etc. Chinese cardiovascular magazine 1998, (1), 6-9] and Neferine (Neferine) [Hu Wenshu etc. Chinese pharmacology and toxicology magazine 1992; (2): 107-109] [history night swallow, Wang Jialing etc. Chinese pharmacist 1998; 1 (2): 51], they belong to Dibenzylisoquinolinealkaloids; Has anti-Ca
++, effect such as anti-arrhythmia, vasodilation, anti-hydroxy radical qiao, anticoagulant and thrombosis; Can be used for treating hypertension, irregular pulse, ischemic cardiomyopathy, cerebro-vascular diseases etc.[
3H]-the diltiazem receptors bind experiment showed, Isoliensinine and the anti-Ca of liensinine
++Action intensity is higher than more than 10 times of Tetrrine, and is suitable with diltiazem.
Isoliensinine content is relatively low in the Plumula Nelumbinis, all adopt solvent extration to obtain fat-soluble total alkali early stage in the document, separate monomer whose (preparation property high-efficient liquid phase technique, preparation of lamina or column chromatography) with chromatography again, time-consuming wasted work, the cost costliness, recovery rate is lower, is not suitable for suitability for industrialized production and uses; Isoliensinine is the isomers of liensinine (Liensinine), and both chemical property are quite similar, is difficult to separate in conjunction with salt forming method with solvent extration; Can be made into [Chao Tse-Yuan et al.Scientia Sinica 1962 perchlorate except that rarely seen liensinine in the document; 11 (2): 215] [Pan Pei-Chuan et al.Sinica1962; 11 (3): 321], do not see other report.Alkaloid has pharmaceutical use for generally acknowledged in the Plumula Nelumbinis, but the difficulty that the monomer whose alkaloid extracts then is the major obstacle of its Application and Development of puzzlement.
The purpose of this invention is to provide a kind of low cost, high recovery rate, high-quality, be suitable for from Plumula Nelumbinis, the extracting of suitability for industrialized production, the preparation method of purifying Isoliensinine (Isoliensinine) and liensinine (Liensinine).
The concrete scheme of extracting the preparation method of purifying Isoliensinine and liensinine from Plumula Nelumbinis provided by the invention is:
(1) extracting with Neferine, Isoliensinine, liensinine from Plumula Nelumbinis is the water-insoluble total alkali of main alkali; It is characterized in that:
(2) from the water-insoluble total alkali of gained, isolate the strong phenolic alkaloids that contains Isoliensinine and liensinine;
(3) separate strong phenolic alkaloids with crystallization process and get Isoliensinine and liensinine.
Below by specific embodiment the inventive method is described further.
Figure of description is the process flow sheet of the embodiment of the invention.
Embodiment 1:
Producing Plumula Nelumbinis with Hubei is raw material (lotus nut source mill buys from the Honghu City, Hubei Province), at first selects clean, dry Plumula Nelumbinis 8kg, uses an amount of 3%Na in advance
2CO
3(about 100ml/kg crude drug) deg adds an amount of (about 4000ml/kg) methyl alcohol (or ethanol) again and soak a week successive soaking three times under room temperature.Merge the methyl alcohol soak solution, reclaim methyl alcohol, debris is transferred pH to 2_3 with 3% hydrochloric acid, filters, and filtrate is used ether defatting, and continues following steps:
1. the separation of water-insoluble total alkaloids
With acidic solution after the above-mentioned degreasing, transfer about pH to 9 with strong aqua, with each 5000ml of chloroform extraction * 3 times, reclaim chloroform, distilled water is washed till nearly neutrality, reclaims chloroform, water-insoluble total alkali 54.4g.
2. the separation of strong phenolic alkaloids
Total alkali 54.4g is dissolved in 1% sodium hydroxide, with chloroform extraction 1500ml * 1 time, get the sodium hydroxide layer, regulate pH to 9 with ammonium chloride, have a large amount of precipitations to separate out, usefulness extracted with diethyl ether 2500ml * 5 times, ether layer is washed till neutrality with distilled water, reclaim ether, residue gets strong phenolic alkaloids 29.4g after vacuum-drying.
3. crystallization process separates Isoliensinine and liensinine
Phenolic alkaloids is dissolved in the anhydrous methanol, is cooled to 4 ℃ on the ice-water bath, regulate pH to 2_3, be statically placed in (4 ℃) crystallization in the refrigerator with perchloric acid, the leaching crystallization, periodic crystallisation in the methyl alcohol (or ethanol) gets the liensinine perchlorate, white crystals.Dissociate into alkali, get liensinine.
To remove by filter the mother liquor of crystallization (liensinine perchlorate), transfer pH to separate out with ammoniacal liquor to a large amount of precipitations, extracted with diethyl ether 500ml * 3 time (or chloroform extraction 500ml * 2 time), ether layer is washed till neutrality through distilled water, reclaim ether, residue gets unformed powder after vacuum-drying.Be dissolved in benzene and the ethyl acetate mixed solvent (95: 5), add concentrated hydrochloric acid, regulate pH to 2_3,4 ℃ leave standstill crystallization, the leaching crystallization, and periodic crystallisation in the water gets the Isoliensinine hydrochloride, the crystallization of white pin type.Dissociate into alkali, get Isoliensinine.
The affirmation of the inventive method extracting substance (physics and chemistry and wave spectrum are identified):
(1) Isoliensinine
Main physicochemical constant and wave spectrum are counted a tree name: white unformed powder (ether), MP:70-72 ℃; Isoliensinine hydrochloride (water): the crystallization of white pin type, MP:195-197 ℃.The Rf value is 0.52 (silica gel G-CMC-Na plate, benzene: ethyl acetate: diethylamine launches at 7: 2: 1), and the 254nm UV-irradiation shows blue look fluorescence.UVλ
max 95％EtOHnm?284.5，256.4nm。IRV
max KBrcm
-1，3450(-OH)、2960、1620、1520、1252、1125。MS?M/Z：609(M
-1)、489、297、266、192、177、148、121、77、42。NMR (CDCl
3) δ ppm:2.49,2.37 (each 3H, 2 * N-CH
3); 3.78 (6H, 2 * O-CH
3); 3.72 (3H, O-CH
3) 6.00 (2H, broad peak 2 *-OH), and 6.92-6.31 (11H, virtue-H).Above-mentioned data and document [M.Tomita et al.TetrahedronLetters:No.37 1964; 2637-2642] [Guo Maodi etc. herbal medicine 1984; 15 (7): 291] [Pan Jingxian etc. sharp college journal 1989 is cured in Beijing; 21 (5): 401] [Wang Jialing etc. CHINA JOURNAL OF CHINESE MATERIA MEDICA 1991; 16 (11): 673-675] conform to, so can be defined as Isoliensinine (Isoliensinine), its chemical name: phenol ,-4-[(1,2,3,4-tetrahydrochysene-6-methoxyl group-7-hydroxy-2-methyl-1-isoquinoline 99.9)] methyl-2-[(1,2,3,4-tetrahydrochysene-1-[(4-p-methoxy-phenyl) methyl]-6-methoxyl group-2-methyl-7-isoquinoline 99.9) the oxygen base]-, [R-(R*, R*)]; Molecular weight is: 610.72; Molecular formula is: C
37H
42N
2O
6Chemical structural formula is:
High performance liquid phase and thin layer scanning: the Isoliensinine content of this law extraction is 93_96%.
High performance liquid phase: Water ' s company 810 types, YWG
18Post, moving phase: methyl alcohol: potassium phosphate salt damping fluid (73: 27), triethylamine is transferred pH to 9; Column temperature: 28 ℃, flow velocity: 1.0ml/min, pump pressure: 5000Psi.Compare Isoliensinine content 92_95% with standard substance.
Thin layer scanning: CS-930 type scanner, reflection method are measured, and signal is machine automatic integration and provide area under curve as calculated, λ max:287nm, the same confirmation of thin-layer method and condition: with standard substance relatively, Isoliensinine content 94_97%.
(2) liensinine:
Main physicochemical constant and wave spectrum are counted a tree name: white unformed powder (ether), and MP:95-98 ℃, the Rf value is 0.42 (silica gel G-CMC-Na plate, benzene: ethyl acetate: diethylamine launches at 7: 2: 1), the 254nm UV-irradiation shows blue look fluorescence.UVλ
max 95％EtOH?nm282.4，，277.3，250.3nm；IRV
max KBrcm
-1，3440，2940、1610、1510、1250、1120。MS?M/Z：611(M
+1)、503、297、206、192、176、162、146、107。NMR (CDCl
3) δ ppm:2.57,2.54 (each 3H, unimodal 2 * N-CH3); 3.42,3.83,3.89 (each 3H, unimodal 3 * O-CH3), 6.48-7.02 (11H, multiplet, 11 virtues-H).Gained data and document [Chao Tse-Yuan et al.ScientiaSinica 1962; 11 (2): 215] [Pan Pei-Chuan et al. Scicntia Sinica1962; 11 (3): 321S] [Guo Maodi etc. herbal medicine 1984; 15 (7): 291] [Pan Jingxian etc. journal of Beijing Medical University 1989; 21 (5): 401] [Zhang Xianzhou, Wang Jialing etc. pharmaceutical analysis magazine 1991; 11 (3): 183] [Wang Jialing etc. CHINA JOURNAL OF CHINESE MATERIA MEDICA 1991; 16 (11): 673-675] [Gu Chuanhong. he. pharmaceutical journal (day) 1965; 85 (4): 353] [Wu Ji continent king's Jiangling etc. herbal medicine 1,998 29 (6): 364] conform to, so be defined as liensinine (Liensinine), it is English by name: Liensinine; Its chemistry is by name: phenol ,-4-[(1,2,3,4-tetrahydrochysene-6,7-dimethoxy-2-methyl isophthalic acid-isoquinoline 99.9)] methyl-2-[(1,2,3,4-tetrahydrochysene-1-[(4-hydroxyphenyl) methyl]-6-methoxyl group-2-methyl-7-isoquinoline 99.9) the oxygen base]-, [R-(R*, R*)]; Molecular weight: 610.0; Molecular formula is: C
37H
42N
2O
6Chemical structural formula is:
High performance liquid phase (condition is the same) and thin layer scanning (λ: 290nm, condition is the same) confirm: compare with standard substance, the liensinine content of this law extraction is 88-93%.
Embodiment 2:
The comparison of best water-insoluble total alkali extraction method.
Adopting benzene benzene lixiviation process, methyl alcohol lixiviation process, methanol eddy method, 0.5% hydrochloric acid water leaching method respectively, is index with water-insoluble total alkali extract weight, and the water-insoluble total alkali extraction scheme of the best is contrasted.Every method is got 5 samples, and every sample takes by weighing Plumula Nelumbinis crude drug 50 grams, and all same lot number Plumula Nelumbinis crude drug is got in experiment, soaked 6 days under the room temperature, and successive soaking 3 times, or refluxed 8 hours, continuous 3 times, decompression and solvent recovery.Total alkaline extraction adopts 0.5% dissolving with hydrochloric acid, removes by filter the non-alkaloid part, and acid filtrate is transferred about Ph to 9 with strong aqua, fully produces flocks, and chloroform extraction 5 times reclaims chloroform, and residue (being water-insoluble total alkali extract) drying is weighed.The results list is as follows:
The total alkali comparison that different methods extracts (X ± SD, n=5)
| Method | Total alkali weight (g) |
| The benzene lixiviation process | ????0.37±0.08 |
| Methyl alcohol soaks division | ????0.42±0.06 |
| The sour water lixiviation process | ????0.39±0.11 |
| The methanol eddy method | ????0.40±0.09 |
Result relatively is that the methyl alcohol lixiviation process is most effective, and good stability.
Embodiment 3:
The Plumula Nelumbinis of producing with Ruichang, Jiangxi, yueyang, hunan is a raw material respectively, according to embodiment 1 described extraction process step, obtains the result identical with embodiment 1.
Provided by the inventionly from Plumula Nelumbinis, extract, the method for purifying Isoliensinine and liensinine, obtain fat-soluble total alkali with adopting solvent extration existing early stage, the method of separating monomer whose (preparation property high-efficient liquid phase technique, preparation of lamina or column chromatography) with chromatography is compared again, has that cost is low, recovery rate is high, product are of fine quality---content greater than 90%, be suitable for outstanding advantage such as suitability for industrialized production.
Isoliensinine (Isoliensinine, IL) effect of anti-experimental character irregular pulse and Mechanism Study result and conclusion.
One, Isoliensinine (Isoliensinine, IL) effect of anti-experimental character irregular pulse
1.IL the ARR influence of cavy that ouabain is brought out
Ouabain brings out irregular pulse dosage
Drugs????VP(μg/kg)?????VF(μg/kg)????lethal(μg/kg)
(mg/kg)
NS??????182.8±20.8????278.1±59.0?????332.4±64.3
Qui5????235.6±26.8????329.4±39.9?????365.0±47.6
IL1.25??216.7±64.0????319.2±57.8?????364.4±44.7
IL2.5???288.8±66.5????374.8±37.3?????402.7±33.3
2.IL to CaCl
2(3.5%CaCl
2, 14mg/kg,
Iv, the effect of the rat ventricular that 10s) brings out
Dead survival number quivers in group example number chamber
NS??????????8???????7???????7???????1
IL5mg/kg????8???????1???????1???????7
3.IL coronary ligation is irritated again the effect of the rat ventricular that brings out
The medicine example number chamber dead irregular pulse of quivering
(mg/kg) take place number/time length (min)
NS??????????8???????6???????2?????7/12.8±5.1
Qui?8???????8???????1???????0?????6/6.1±4.8**
IL??3???????8???????0???????0?????2/1.5±0.7**
4.IL to Adr (0.01%Adr, 0.06ml/kg, iv,
The ARR influence of the rabbit of 5s) bringing out
Medicine example number irregular pulse
(mg/kg) take place number/time length (min)
NS?????????8?????????8/3.2±1.2
Qui?8??????8?????????6/1.8±0.6*
IL??3??????8?????????8/0.64±1.1**
5.IL the influence of the rat ventricular that napelline is brought out
The irregular pulse dosage that napelline brings out (μ g/kg)
The death of quivering of Drugs (mg/kg) chamber speed and chamber
NS?????????????42.8±4.6?????153.8±51.4
Qui?5??????????46.6±4.2?????216.4±53.6
IL?2.5?????????42.7±5.8?????181.7±68.4
Two, Isoliensinine (Isoliensinine, IL) effect of myocardial cell's action potential
1. (Isoliensinine is IL) to the influence of guinea-pig heart myocyte action potential for Isoliensinine
IL (1-100 μ mol/L) is the APD20 of cavy papillary muscles of right ventricle action potentials of cells but the reduction of dose-dependently ground is exsomatized, and other indexs are not almost had effect.This is similar to contrast medicine verapamil.Show that it has the effect of calcium entry blocker sample.
Table: IL is to the influence of the cavy papillary muscles of right ventricle action potentials of cells that exsomatizes
Isolinsinine(μmol/L)Paramters
0????????????1????????????3????????????10?????????????30????????????100Vmax(V/s)???183.2±62.6??178.5±62.3???170.5±65.2???155.4±63.6????151.4±59.6????146.8±45.7OS(mV)??????28.3±10.1???27.8±13.3????26.4±13.3????26.1±14.1?????25.3±14.1?????23.8±11.9RP(-mV)?????83.7±5.4????84.1±6.6?????84.1±8.8?????82.2±12.8?????85±8.7????????85.6±7.2APA(mV)?????111.3±7.8???112.4±9.8????111.7±9.6????110.0±10.3????111.2±10.4????109.2±8.4APD
20(ms)??105.4±24.1??101.2±23.6???93.3±16.3
*??86.4±21.6
*???83.2±17.3
**??81.1±25.3
**APD
50(ms)??181.2±19.5??171.5±21.1???167.3±19.2
*?156.3±26.7
*??148.2±31.4
**?141.7±33.4
**APD
90(ms)??217.3±21.2??198.2±30.1???199.8±25.4???193.8±28.2????187.6±32.58
*?177±4.9
*
2. (Isoliensinine is IL) to the influence of the stripped guinea pig papillary muscle slow response action potential of high K+ partial depolarization for Isoliensinine
IL (1-100 μ mol/L) but dose-dependently ground reduces maximum climbing speed (Vmax), overshot (OS), the action potential amplitude (APA) of the stripped cavy papillary muscles of right ventricle cell slow response action potential of high K+ (24mmol/L KCl) partial depolarization, IL3-10 μ mol/L promptly has tangible effect (P＜0.05 or 0.01).IL100 μ mol/L just has obvious prolongation effect to Action Potential Duration (APD).Show that IL mainly suppresses flow of calcium ions, less inhibition sodium ion inflow, IL differs 10 times to two kinds of inhibiting effective concentration of electric current.
Table: IL to the influence of papillary muscle slow response action potential (X ± SD, n=6)
concentrntion(μmol/L)Paramters
0???????????3?????????????10???????????30???????????????100Vmax(V/s)????42.8±15.7???37.8±13.8????31.8±10.2
*????27.8±6.9
**?????22.3±5.3
**OS(mV)???????26.1±7.6????20.5±61
*????16.6±10.3
**???12.8±12.6
**????9.2±13.1
**RP(-mV)??????52.7±7.5????52.3±8.0??????54.0±10.3??????52±8.3??????????53.8±8.4APA(mV)??????78.7±4.1????71.4±4.3
*???70.1±6.1
**????66.0±8.1
**?????60.2±9.4
**APD
20(ms)???62.3±19.2???64.5±18.6????67.0±26.4??????75.5±29.4
*?????79.8±32.6
*APD
50(ms)???117±44.1????119±39???????117±34?????????127±58??????????133±51
*APD
90(ms)???140±47??????147±41???????143±41?????????181±93??????????186±102
*
Claims (7)
1. preparation method who extracts purifying Isoliensinine and liensinine from Plumula Nelumbinis may further comprise the steps:
(1) extracting with Neferine, Isoliensinine, liensinine from Plumula Nelumbinis is the water-insoluble total alkali of main alkali; It is characterized in that:
(2) from the water-insoluble total alkali of gained, isolate the strong phenolic alkaloids that contains Isoliensinine and liensinine;
(3) separate strong phenolic alkaloids with crystallization process and get Isoliensinine and liensinine.
2. the preparation method who extracts purifying Isoliensinine and liensinine from Plumula Nelumbinis according to claim 1 is characterized in that extracting that water-insoluble total alkali adopts is the methyl alcohol lixiviation process from Plumula Nelumbinis.
3. the preparation method who extracts purifying Isoliensinine and liensinine from Plumula Nelumbinis according to claim 1 is characterized in that extracting that water-insoluble total alkali adopts is the methanol eddy method from Plumula Nelumbinis.
4. the preparation method who extracts purifying Isoliensinine and liensinine from Plumula Nelumbinis according to claim 1 is characterized in that extracting that water-insoluble total alkali adopts is that sour water leaches or the benzene lixiviation process from Plumula Nelumbinis.
5. according to claim 1,2, the 3 or 4 described preparation methods that from Plumula Nelumbinis, extract purifying Isoliensinine and liensinine, it is characterized in that the method for separating strong phenolic alkaloids from water-insoluble total alkali is: water-insoluble total alkali is dissolved in the sodium hydroxide of 1-1.5%, use chloroform extraction, separate chloroform layer and water layer, get the sodium hydroxide layer, regulate pH to 8-9 with ammonium chloride, there are a large amount of precipitations to separate out, with extracted with diethyl ether for several times, separate ether layer, be washed till neutrality with distilled water, reclaim ether, residue gets strong phenolic alkaloids after vacuum-drying.
6. according to claim 1,2, the 3 or 4 described preparation methods that from Plumula Nelumbinis, extract purifying Isoliensinine and liensinine, it is characterized in that separating the method that strong phenolic alkaloids gets Isoliensinine and liensinine with crystallization process is: phenolic alkaloids is dissolved in the anhydrous methanol, on ice-water bath, be cooled to 4 ℃, drip perchloric acid and regulate pH to 2_3, be statically placed in 4 ℃ of crystallizatioies, the leaching crystallization, periodic crystallisation in methyl alcohol or the ethanol gets the liensinine perchlorate, white crystals, dissociate into alkali, get liensinine; To remove by filter crystallization---the mother liquor of liensinine perchlorate, transfer pH to separate out with ammoniacal liquor, ether (or chloroform) extraction to a large amount of precipitations, ether layer is washed till neutrality through distilled water, reclaims ether, and residue gets unformed powder after vacuum-drying, this powder is dissolved in benzene and the ethyl acetate mixed solvent, adds concentrated hydrochloric acid, regulate pH to 2_3, leave standstill crystallization, leaching crystallization, periodic crystallisation in the water in 4 ℃, get the Isoliensinine hydrochloride, the crystallization of white pin type dissociates into alkali, gets Isoliensinine.
7. the preparation method who from Plumula Nelumbinis, extracts purifying Isoliensinine and liensinine according to claim 5, it is characterized in that separating the method that strong phenolic alkaloids gets Isoliensinine and liensinine with crystallization process is: phenolic alkaloids is dissolved in the anhydrous methanol, on ice-water bath, be cooled to 4 ℃, drip perchloric acid and regulate pH to 2_3, be statically placed in 4 ℃ of crystallizatioies, the leaching crystallization, periodic crystallisation in methyl alcohol or the ethanol gets the liensinine perchlorate, white crystals, dissociate into alkali, get liensinine; To remove by filter crystallization---the mother liquor of liensinine perchlorate, transfer pH to separate out with ammoniacal liquor, ether (or chloroform) extraction to a large amount of precipitations, ether layer is washed till neutrality through distilled water, reclaims ether, and residue gets unformed powder after vacuum-drying, this powder is dissolved in benzene and the ethyl acetate mixed solvent, adds concentrated hydrochloric acid, regulate pH to 2_3, leave standstill crystallization, leaching crystallization, periodic crystallisation in the water in 4 ℃, get the Isoliensinine hydrochloride, the crystallization of white pin type dissociates into alkali, gets Isoliensinine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98121706A CN1117735C (en) | 1998-12-14 | 1998-12-14 | Process for extracting purified isoliensinine and liensinine from plumula nelumbinis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98121706A CN1117735C (en) | 1998-12-14 | 1998-12-14 | Process for extracting purified isoliensinine and liensinine from plumula nelumbinis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1257070A true CN1257070A (en) | 2000-06-21 |
| CN1117735C CN1117735C (en) | 2003-08-13 |
Family
ID=5227262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98121706A Expired - Fee Related CN1117735C (en) | 1998-12-14 | 1998-12-14 | Process for extracting purified isoliensinine and liensinine from plumula nelumbinis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1117735C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101786984A (en) * | 2010-03-31 | 2010-07-28 | 聊城大学 | Method for extracting liensinine, isoliensinine and neferine from lotus plumule |
| CN101791335A (en) * | 2010-04-08 | 2010-08-04 | 江西民康制药有限公司 | Total alkaloid mixture sourcing from Chinese medicina plant lotus plumule and extraction and preparation method thereof |
| CN104306455A (en) * | 2014-11-07 | 2015-01-28 | 中南民族大学 | Lotus plumule chloroform extract and preparation method and use thereof |
| CN104744367A (en) * | 2015-04-03 | 2015-07-01 | 辽宁大学 | Flash extraction method of lotus plumule alkaloid |
| CN114276293A (en) * | 2022-01-09 | 2022-04-05 | 福建中医药大学 | Preparation and purification method of neferine perchlorate |
| CN114349696A (en) * | 2022-01-09 | 2022-04-15 | 福建中医药大学 | Preparation and purification method of lotus nut total alkali perchlorate |
| CN114349697A (en) * | 2022-01-09 | 2022-04-15 | 福建中医药大学 | Preparation and purification method of isoliensinine perchlorate |
| CN114349698A (en) * | 2022-01-09 | 2022-04-15 | 福建中医药大学 | Preparation and purification method of liensinine perchlorate |
-
1998
- 1998-12-14 CN CN98121706A patent/CN1117735C/en not_active Expired - Fee Related
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101786984A (en) * | 2010-03-31 | 2010-07-28 | 聊城大学 | Method for extracting liensinine, isoliensinine and neferine from lotus plumule |
| CN101786984B (en) * | 2010-03-31 | 2011-09-07 | 聊城大学 | Method for extracting liensinine, isoliensinine and neferine from lotus plumule |
| CN101791335A (en) * | 2010-04-08 | 2010-08-04 | 江西民康制药有限公司 | Total alkaloid mixture sourcing from Chinese medicina plant lotus plumule and extraction and preparation method thereof |
| CN104306455A (en) * | 2014-11-07 | 2015-01-28 | 中南民族大学 | Lotus plumule chloroform extract and preparation method and use thereof |
| CN104306455B (en) * | 2014-11-07 | 2016-06-22 | 中南民族大学 | A kind of Plumula Nelumbinis chloroform extract and its production and use |
| CN104744367A (en) * | 2015-04-03 | 2015-07-01 | 辽宁大学 | Flash extraction method of lotus plumule alkaloid |
| CN114276293A (en) * | 2022-01-09 | 2022-04-05 | 福建中医药大学 | Preparation and purification method of neferine perchlorate |
| CN114349696A (en) * | 2022-01-09 | 2022-04-15 | 福建中医药大学 | Preparation and purification method of lotus nut total alkali perchlorate |
| CN114349697A (en) * | 2022-01-09 | 2022-04-15 | 福建中医药大学 | Preparation and purification method of isoliensinine perchlorate |
| CN114349698A (en) * | 2022-01-09 | 2022-04-15 | 福建中医药大学 | Preparation and purification method of liensinine perchlorate |
| CN114349696B (en) * | 2022-01-09 | 2023-10-03 | 福建中医药大学 | Preparation and purification method of lotus nut total alkali perchlorate |
| CN114349697B (en) * | 2022-01-09 | 2023-12-22 | 福建中医药大学 | Preparation and purification method of isoliensinine perchlorate |
| CN114349698B (en) * | 2022-01-09 | 2024-01-26 | 福建中医药大学 | Preparation and purification method of liensinine perchlorate |
| CN114276293B (en) * | 2022-01-09 | 2024-01-26 | 福建中医药大学 | Preparation and purification method of methyl lotus plumule perchlorate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1117735C (en) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1164582C (en) | Process for preparing danshen salviandic acid | |
| CN1117735C (en) | Process for extracting purified isoliensinine and liensinine from plumula nelumbinis | |
| CN101054384A (en) | Method for extracting ginkgolide B from gingkgo leaf or gingkgo leaf extract | |
| CN1891240A (en) | Chinese medicine composition containing multi glossy ganoderma active constituents and its preparing method | |
| CN1112366C (en) | Extraction of gensenoside | |
| CN1958555A (en) | Method for preparing salviol acid A | |
| CN1785308A (en) | Extraction technology of plant total alkaloid extract having anti tumour action and its preparation | |
| CN1733054A (en) | Dogwood fruit extract and its preparation process | |
| CN1169826C (en) | Magnesium isoglycyrrhetate and its preparing process and usage | |
| CN1189176C (en) | Astragalus root methyl-glycoside composition and preparation method | |
| CN101057661A (en) | Extraction method for alpha-linolenic acid and preparation | |
| CN1515582A (en) | Preparation method of low-acid ginkgo leaf extract | |
| CN1676133A (en) | Doxufylline for injection and its preparing method | |
| CN1252073C (en) | Process for preparation of garcinia acid | |
| CN1081922C (en) | Medicinal composition containing ginsenoside Re, preparation and usage thereof | |
| CN1884246A (en) | Method for extracting diaryl heptane compounds from galangas | |
| CN114478675A (en) | Method for separating cholesterol from fish oil leftovers | |
| CN1706836A (en) | Process of separating fucoxanthin from algae | |
| CN1515581A (en) | Preparation method of ginkgo leaf extract | |
| RU2416423C1 (en) | Method for preparing chlorophylliptum | |
| CN1117734C (en) | Process for extracting lotucine from plumula nelumbinis | |
| CN1473828A (en) | Porocess for extracting matrine and sophoridine from sophora alopecuroide | |
| CN1966484A (en) | New phenoxy eicosanoic acid derivative and its medical use | |
| CN1699400A (en) | Toosendanin derivatives and preparing process and application thereof | |
| CN1275978C (en) | Oslasodine hydrochloride preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |